EUVIMEDObjevte EUVIMED
Metaanalyse

P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials.

Daniele Giacoppo, Felice Gragnano, Watanabe, Hirotoshi, Takeshi Kimura, Kang, Jeehoon, Park, Kyung-Woo, Hyo-Soo Kim, Pettersen, Alf-Åge and 5 more

Open Access CRIS of the University of Bern · 2025-06-04

DOI: 10.48620/88433 ↗

At a glance

Metaanalyse in Open Access CRIS of the University of Bern, published on 2025-06-04. Written by Daniele Giacoppo and 16 co-authors. Cited 1 times so far (Crossref).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To assess the long term comparative effectiveness of P2Y12 inhibitor monotherapy compared with aspirin monotherapy in patients after percutaneous coronary intervention (PCI) and discontinuation of dual antiplatelet therapy (DAPT).

Design

Individual participant data (IPD) meta-analysis of randomised clinical trials.Data Sources PubMed/Medline, Scopus, Web of Science, and Ovid/Embase.Eligibility Criteria For Selecting Studies Randomised trials investigating monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention of ischaemic events in patients with coronary artery disease who underwent PCI.Data Extraction And Synthesis Anonymised IPD were extracted and transferred to the coordinating centre by dedicated electronic spreadsheets. Data were primarily combined by mixed effects models (one stage analysis) and complemented with multivariable mixed effects models and two stage analyses based on random effects models. The primary and co-primary outcomes were a composite of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding, respectively. The secondary outcomes included a net composite of adverse cardiac and cerebrovascular events (NACCE), derived from the combination of the primary and co-primary outcomes, and individual ischaemic and bleeding events.

Results

A total of 16 117 patients assigned to P2Y12 inhibitor or aspirin monotherapy after PCI and completion of the recommended DAPT regimen (median duration of 12 months) in five randomised trials were included. At a median follow-up of 1351 days (interquartile range 373-1791 days), P2Y12 inhibitor monotherapy was associated with a lower risk of MACCE compared with aspirin monotherapy (one stage analysis: hazard ratio 0.77 (95% confidence interval (CI) 0.67 to 0.89), P

Subjects

P2Y12 inhibitorsaspirinpercutaneous coronary interventionsecondary preventioncoronary artery diseasemajor adverse cardiac and cerebrovascular eventsmajor bleedingischemic eventscomparative effectivenessindividual patient data meta-analysis

Cite

APA

Giacoppo, D., Gragnano, F., Watanabe, Hirotoshi, Kimura, T., Kang, Jeehoon, Park, Kyung-Woo, Kim, H., Pettersen, Alf-Åge, Bhatt, D. L., Pocock, S., Mehran, R., Valgimigli, & Marco (2025). P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. Open Access CRIS of the University of Bern. https://doi.org/10.48620/88433

Vancouver

Giacoppo D, Gragnano F, Watanabe, Hirotoshi, Kimura T, Kang, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. Open Access CRIS of the University of Bern. 2025. doi:10.48620/88433

BibTeX
@article{Giacoppo2025,
  author = {Giacoppo, Daniele and Gragnano, Felice and Watanabe and Hirotoshi and Kimura, Takeshi and Kang and Jeehoon and Park and Kyung-Woo and Kim, Hyo-Soo and Pettersen and Alf-Åge and Bhatt, Deepak L. and Pocock, Stuart and Mehran, Roxana and Valgimigli and Marco},
  title = {P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials},
  journal = {Open Access CRIS of the University of Bern},
  year = {2025},
  doi = {10.48620/88433}
}
Start for free →